Position
SYNTAX RESEARCH, INC. in Lexicon Pharmaceuticals, Inc.
Back to the book · All holders of LXRX
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark $58$1.15 → $1.56
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 142 | $164 | — | — | — | 0.0% |
| Q1 2026 | 142 | $222 | $1.56 | $58 | $0 | 0.0% |